ABSTRACT
The controversy continues, with no clear
resolution in sight. Meanwhile, more and
more governments move towards policies that
insist upon the demonstration of cost-
effectiveness as a prerequisite for approval for
reimbursement (Maynard and Bloor, 1998).
